Development of guidelines on good manufacturing of biomedical cell products
https://doi.org/10.12737/article_59f035fb9ec0d8.64599419
Abstract
The article presents the essence of draft of the Guidance of good manufacturing practices of biomedical cell products (BMCP) (GMP/GTP guideline) harmonized with the international requirements, which contains the basic quality and safety standards of clinical application of these products. These regulations prescribe the requirements for institutions engaged in one or more stages of BMCP production and allow to avoid any risk of contamination of cells, tissues and finished product. The aim of this work is to develop a methodology for BMCPs' quality assurance framework. Materials and methods. The main subjects of research are national and international laws and regulations, publications on quality assurance systems of cell products, problems of BMCP manufacturing and validation. Results. The draft Guidance of good manufacturing practices of BMCP (GMP/GTP guideline), including specific requirements to donor determination, biomaterial sampling and its transportation to the manufacture, to risk management system, traceability system, to processing, definition of minimally manipulated BMCP, requirements to incoming control, continuous in-process control and control of finished BMCP, to pharmacovigilance system were developed. Specific features of the manufacture of test products for non-clinical and clinical studies are described. Assessment elements for certification prior to release of each batch of test BMCP were clarified. Recommendations on the introduction of a product coding system according to ISBT 128 Standard are given in this work.
About the Authors
M. A. Tulina
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
N. V. Pyatigorskaya
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Брюховецкий А.С. Мнения специалистов // Клеточная и тканевая инженерия. - 2010. - № 5 (4). -С. 9-15
2. О биомедицинских клеточных продуктах: Федеральный закон от 23 июня 2016 г. № 180-ФЗ // Российская газета. - 2016. - № 139
3. Продукция медицинской промышленности. Технологические регламенты производства. ОСТ 6402-003-2002. - М.: Изд-во Министерства промышленности, науки и технологии РФ, 2002. - 84 с
4. Система менеджмента качества. Требования. ГОСТ Р ИСО 9001-2011. - М.: Стандартинформ, 2012. -28 с
5. Скворцова В.И. Современный этап развития биомедицины // Журнал «Медицина». - 2015. -№ 3 (4). - С. 1-7
6. Чистые помещения и связанные с ними контролируемые среды. Часть 4. Проектирование, строительство и ввод в эксплуатацию. ГОСТ Р ИСО 14644-4-2002. - М.: Изд-во стандартов, 2002. - 40 с
7. Commission Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. (2005). Official Journal of the European Union, L102, 48-58.
8. Guidance for industry: Current Good Tissue Practice (CGTP) and additional requirements for manufacturers of human cells, tissues, and cellular and tissue-based products (HCT/Ps). (2011). US Food and Drug Administration
9. Guidance for industry: Eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). (2007). US Food and Drug Administration, 70 p.
10. Guidance for industry: Investigating and reporting adverse reactions related to human cells, tissues, and cellular and tissue-based products (HCT/Ps) regulated solely under Section 361 of the Public Health Service Act and 21 CFR Part 1271. (2015). US Food and Drug Administration, 20 p.
11. Guide to good manufacturing practice for medicinal products. Part I, Annex 2. Manufacture of biological medicinal substances and products for human use. (2014). Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (P1C/S), 180 p.
12. Guideline on human cell-based medicinal products. (2008). EMEA, Committee for Human Medicinal Products, 25 p.
13. Günther C., Huss R., Hauser A. (2016) Advances in pharmaceutical cell therapy: principles of cell-based biopharmaceuticals. World Scientific, 524 p.
14. Kolkundkar US, Gottipamula A, Majumdar J. (2014). Cell therapy manufacturing and quality control: current process and regulatory challenges. J. Stem Cell Res. Ther., 260, 75-82.
15. Labeling of cellular therapy products. (2013), ISBT 128 Standard. ICCBBA, ST-004, 39, 123 p.
16. WHO Expert Committee on Biological Standardization. (2016). WHO good manufacturing practices for biological products: sixty-sixth report. Annex 2, WHO Technical Report Series № 999. Geneva, 292 p.
Review
For citations:
Tulina M.A., Pyatigorskaya N.V. Development of guidelines on good manufacturing of biomedical cell products. Acta Biomedica Scientifica. 2017;2(3):58-62. (In Russ.) https://doi.org/10.12737/article_59f035fb9ec0d8.64599419
Views:
627
Email this article 
